ArticleRSC advances2025
Development of a point-of-care-testing platform: localized surface plasmon resonance biosensor for rapid ABO/Rh blood typing.
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Rapid Electrochemical Impedance Detection of the MiACS omega · 2026Article
- An Accumulation Pretreatment-Free POCT Biochip for Visual and Sensitive ABO/Rh Blood Cell Typing.Biosensors · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Point-of-care testing (POCT) devices are crucial for clinical diagnosis. Presently, clinical biochemical testing heavily relies on advanced analytical equipment, often necessitating bulky machinery and extended assay periods. This study presents a localized surface plasmon resonance biosensor-based POCT platform that integrates microfluidic methods for rapid and cost-effective detection of ABO/Rh blood types. The autonomous system enables high-throughput detection of ABO/Rh blood types with high specificity and sensitivity within 20 minutes using a spectrum based readout. Additionally, we have integrated eight internal microfluidic channels into the portable system to facilitate a high-throughput detection solution. Moreover, the incorporation of microfluidic channels minimizes sample cross-contamination, thereby enhancing detection precision. We believe this rapid, convenient, and cost-effective blood typing platform can serve as a valuable tool in clinical POCT applications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.